Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2018 - 2026)

Allogene Therapeutics has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $396.0 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $396.0 million, down 22.05% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.7 billion (down 24.88% YoY), and the FY2025 annual result was $415.9 million, down 24.2% from the prior year.
• Liabilities and Shareholders Equity came in at $396.0 million for Q1 2026 at Allogene Therapeutics, down from $415.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $978.1 million in Q1 2022 to a low of $396.0 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $642.8 million (2023), against an average of $654.7 million.
• Peak annual rise in Liabilities and Shareholders Equity reached 13.37% in 2025, while the deepest fall reached 27.25% in 2025.
• Allogene Therapeutics' Liabilities and Shareholders Equity stood at $821.6 million in 2022, then decreased by 21.76% to $642.8 million in 2023, then fell by 14.64% to $548.7 million in 2024, then slipped by 24.2% to $415.9 million in 2025, then fell by 4.8% to $396.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $396.0 million (Q1 2026), $415.9 million (Q4 2025), and $439.8 million (Q3 2025), per Business Quant data.